Hypovarian reserve function (DOR), also known as ovarian hypofunction, often refers to a serum follicle stimulating hormone (FSH) level of 10 U/L or more in the early follicular phase or a number of sinus follicles (AFC) <5 on both sides. Since DOR may be the precursor stage of premature ovarian failure (POF) and seriously affects female fertility, it has become a hot and difficult research topic in the field of gynecological reproductive endocrinology. The causes of hypovarian reserve function are poorly understood and may be related to genetic factors, medical factors such as radiotherapy or surgery, impaired folliculogenesis due to psychological and environmental factors, and low or depleted oocyte reserve, but some patients with DOR have idiopathic causes. Recent literature suggests that risk factors for the development of DOR include late childbearing age (>35 years), family history of early menopause, chromosomal abnormalities, carriers of pre-mutations in the FMR1 gene, history of ovarian damaging diseases (e.g., endometriosis, pelvic inflammatory disease, etc.) or surgery, history of radiotherapy, and smoking habits. It is worth mentioning that age >35 years is now a clinically recognized predictor of female reproductive aging, as stated in the new 2015 ACOG clinical practice guideline “Ovarian Reserve Testing”, which states that women with fertility requirements who are >35 years old but have not conceived within 6 months are at high risk for DOR and need to undergo active ovarian function testing. The need for active ovarian function testing and treatment interventions is essential. The choice of a rational fertility method is increasing due to the delayed age of women at childbearing and social and environmental factors, and DOR is becoming a special population for assisted reproductive treatment. Because of the dramatic decrease in the number of sinus follicles, the rate of ovarian hyporesponsiveness and cycle cancellation has increased significantly. To effectively improve the reproductive outcome of DOR patients, the adoption of a rational treatment plan is one of the challenges in the field of assisted reproduction, especially for older DOR patients has been a challenge for clinicians. Studies related to the adjuvant application of DHEA in DOR patients at the time of IVF have been reported more frequently abroad. Patients were given continuous oral DHEA for 4 months prior to IVF treatment, and the clinical pregnancy rate was found to be significantly higher in the DHEA group compared to the control group. In addition, another recent study suggests that blood basal testosterone levels are positively associated with clinical pregnancy outcomes in women with DOR undergoing IVF treatment. Embryo transfer rates were decreased and pregnancy rates were significantly lower in DOR patients with low testosterone levels. In conclusion, diminished ovarian reserve function is a progressive process, and it takes about 1-6 years from the decline of ovarian reserve function to ovarian failure. In the treatment of other systemic diseases, it is important to consider how to protect the reproductive function of female patients, to prevent the occurrence of medically induced DOR as effectively as possible, and to provide genetic counseling services and early fertility guidance advice to patients with specific genetic abnormalities, especially to their young offspring, in order to improve the fertility and quality of life of infertile patients.